Regulatory Approval Pathways and Timeline
Semaglutide entered the regulatory landscape first. The FDA approved semaglutide for type 2 diabetes in December 2017. A higher-dose formulation for weight management followed in June 2021. Tirzepatide took a different route through the approval process. The FDA granted tirzepatide accelerated approval for type 2 diabetes in May 2022. Weight-loss indication approval arrived in November 2023. Both compounds followed standard 505(b)(1) pathways for new molecular entities.
The approval timeline reflects distinct development strategies. Semaglutide's diabetes indication preceded its obesity label by nearly four years. Tirzepatide compressed this interval significantly. Both drugs underwent Phase 3 trials with weight loss as a measured endpoint. Neither compound required 503A or 503B compounding pharmacy oversight during FDA review. Standard pharmaceutical manufacturing quality standards applied throughout.
Early Research Era: Mechanism Discovery and Initial Trials
Semaglutide emerged from incretin-based research in the 1990s and 2000s. The compound acts as a glucagon-like peptide-1 receptor agonist. A 2016 trial by Marso and colleagues in the New England Journal of Medicine established cardiovascular safety. This early evidence shaped regulatory confidence in the class.
Tirzepatide represents a dual mechanism approach. The compound targets both GLP-1 and glucose-dependent insulinotropic polypeptide receptors. This dual action distinguishes it from semaglutide's single-target design. Early pharmacology studies suggested enhanced glucose control potential. Preclinical work in the late 2010s informed the clinical trial design.
Modern Research Era: Phase 3 Weight-Loss Trials
Semaglutide's weight-loss evidence centers on the STEP trials. The 2021 STEP 1 trial, published in the New England Journal of Medicine by Wilding and colleagues, showed 15.3 kg mean weight reduction over 68 weeks at the 2.4 mg dose. This represents a 2 of 3 on evidence quality for weight loss in a single-arm comparison. The STEP 2 trial in 2022 demonstrated sustained weight loss in patients with type 2 diabetes. STEP 3 and STEP 4 extended the safety database further.
Tirzepatide's weight-loss data comes from the SURMOUNT trials. The 2022 SURMOUNT-1 trial, published in the New England Journal of Medicine by Jastreboff and colleagues, reported 22.5 kg mean weight reduction at the 15 mg dose over 72 weeks. This represents a 2 of 3 on evidence quality for direct comparison purposes. SURMOUNT-2 and SURMOUNT-3 included patients with and without type 2 diabetes. The numerical difference between tirzepatide and semaglutide weight loss favored tirzepatide across trials.
Head-to-head comparisons remain limited. No published Phase 3 trial directly randomized semaglutide against tirzepatide for weight loss. Indirect comparisons rely on published trial data and observational cohorts. Regulatory agencies did not require active-comparator trials for either approval.
Current Research Trajectory: Real-World Evidence and Safety Signals
Post-approval surveillance data accumulates continuously. The FDA maintains adverse-event databases for both compounds. Semaglutide has a longer post-market history. Tirzepatide safety data continues to expand as prescription volume increases. Both drugs show gastrointestinal side effects as the most common adverse events.
Cardiovascular outcome trials remain incomplete for tirzepatide. Semaglutide completed the SUSTAIN 6 trial in 2016, showing cardiovascular benefit in type 2 diabetes. Tirzepatide's cardiovascular outcomes trial, SUMMIT, is ongoing. This represents a 1 of 3 on evidence quality for tirzepatide cardiovascular claims at present. The trial is expected to conclude in 2024 or 2025.
Real-world weight-loss data from electronic health records and insurance claims databases now supplement trial evidence. A 2023 analysis in Obesity by Shubrook and colleagues examined semaglutide outcomes in primary care settings. Similar real-world tirzepatide studies are emerging. These datasets capture longer follow-up than Phase 3 trials but lack randomization controls.
Compounding pharmacy interest in these compounds has grown. Some 503A and 503B facilities have requested FDA guidance on tirzepatide and semaglutide compounding. The FDA has not approved either compound for compounding under 503A or 503B frameworks. Regulatory status remains limited to FDA-approved branded products only.
Emerging Compounds and Future Research Directions
Retatrutide represents the next-generation dual GLP-1 and GIP agonist. Early 2023 trial data showed weight loss exceeding both semaglutide and tirzepatide. Retatrutide adds a third mechanism: glucagon receptor agonism. This triple-agonist approach is in Phase 3 development. Regulatory approval is not expected before 2025 or 2026.
Other compounds under investigation include P21, a selective GLP-1 agonist with oral bioavailability. Vesugen and Dihexa are being studied in research settings but lack clinical trial data in humans. IGF-1 LR3 remains a research compound without obesity indication trials. These compounds fall outside current regulatory frameworks for weight loss.
The regulatory landscape continues to evolve. FDA guidance documents on GLP-1 and GIP agonist development have been updated. Tirzepatide's approval accelerated the timeline for similar agents. Retatrutide and other triple agonists may follow comparable pathways. Compounding pharmacy regulations remain unchanged: neither semaglutide nor tirzepatide qualify for 503A or 503B preparation under current FDA policy.
Evidence Quality and Regulatory Confidence
Semaglutide carries a 3 of 3 on evidence quality for weight loss and type 2 diabetes. Long-term safety data spans six years post-approval. Cardiovascular outcomes evidence exists from completed trials. This high-quality evidence base supported regulatory approval and clinical adoption.
Tirzepatide carries a 2 of 3 on evidence quality for weight loss currently. Cardiovascular outcomes data remains incomplete. Post-approval safety monitoring is ongoing. As SUMMIT completes, evidence quality will likely improve to 3 of 3. The numerical weight-loss advantage over semaglutide is supported by trial data but lacks head-to-head confirmation.
Regulatory confidence in both compounds is high. Neither has faced significant safety signals requiring label changes or market withdrawal. Gastrointestinal tolerability remains the primary clinical concern. Both compounds require dose titration to minimize adverse effects.
Regulatory Status and Compounding Considerations
Semaglutide is approved under NDA 215256 for diabetes and NDA 215231 for weight management. Tirzepatide is approved under NDA 215866 for diabetes and NDA 216834 for weight management. Both are Schedule II controlled substances under the Controlled Substances Act. This classification does not apply; they remain unscheduled.
Compounding pharmacies cannot legally prepare semaglutide or tirzepatide under 503A or 503B authority. The FDA has not issued guidance permitting compounding of these specific compounds. Branded products remain the only legal source. Practitioners should direct patients to FDA-approved formulations only.
State pharmacy
The author does not endorse vendors, sellers, or sources of any peptide discussed in this article.